Nu Skin: Valuation Is Low, But Challenges Remain
Summarize this article with:
A. Vandendael955 FollowersFollow5ShareSavePlay(8min)CommentsSummaryAfter years of revenue declines, Nu Skin Enterprises has returned to profitability, supported by cost controls and a stronger balance sheet.NUS management is attempting to reposition the business through new products and selective international expansion.Shares trade at a steep discount to peers, reflecting ongoing top-line pressure and uncertainty around a sustained recovery.With revenue still declining and growth yet to reaccelerate, Nu Skin appears best suited for patient investors willing to wait for clearer signs of stabilisation. Guido Mieth/DigitalVision via Getty Images Nu Skin Enterprises, Inc. (NUS) is not an easy stock to love right now. Over the last decade, it has lost 72.76% of its value. At the same time, I don't think that means a company should be ignored completely. After several years of decliningThis article was written byA. Vandendael955 FollowersFollowI am a freelancer with a business education who loves to discover new ideas for long and short term investments."Stop hoping for a promotion that's not coming. Instead, start a business at which you want to work." Sallie KrawcheckAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.